Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News CareDx Inc CDNA

Healthcare Diagnostics & Research
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA... see more

Current News (NDAQ:CDNA)

CareDx Announces Clinical Validation Results for AlloHeme(TM), the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy

Business Wire 3 days ago

CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Business Wire 4 days ago

CareDx to Present AlloHeme(TM) Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings

Business Wire 12 days ago

CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference 

Business Wire January 27, 2026

CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Business Wire January 12, 2026

CareDx and 10x Genomics to Launch ImmuneScape(TM) Program - A Multiomics Research Platform to Decode Transplant Rejection and Drug Response

Business Wire January 7, 2026

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 26, 2025

CareDx Provides Notice of Proposed Derivative Settlement

Business Wire December 18, 2025

SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation

Business Wire November 24, 2025
View More News ››

Opinion & Analysis (NDAQ:CDNA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CDNA)

4 PROMISING BIOTECH STOCKS WITH IMMENSE POTENTIAL!

$CDNA $BCRX $IPSC $DYAI  Clinical-Stage companies offer an exciting investment opportunity with massive upside potential. Most of...
AviseAnalytics - January 14, 2022
View more Bullboard ››

Vanstar Mining Resources Inc.

Vanstar Mining Resources Inc.

Vanstar Mining’s Nelligan gold project joint venture with IAMGOLD (25% VSR/75% IMG), located 60 kilometres SW of Chibougamau, ...
View More »

Podcasts